» Articles » PMID: 20303173

A Distinct Expression of Various Gene Subsets in CD34+ Cells from Patients with Early and Advanced Myelodysplastic Syndrome

Overview
Journal Leuk Res
Date 2010 Mar 23
PMID 20303173
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Gene expression profiles of CD34+ cells were compared between 51 MDS patients and 7 controls. The most up-regulated genes in patients included HBG2, HBG1, CYBRD1, HSPA1B, ANGPT, and MYC, while 13 genes related to B-lymphopoiesis showed down-regulation. We observed in advanced MDS patients decreased expression of genes involved in cell cycle control, DNA repair and increased expression of proto-oncogenes, angiogenic and anti-apoptic genes. The results suggest that increased cell proliferation and resistance to apoptosis together with a loss of cell cycle control, damaged DNA repair and altered immune response may play an important role in malignant clone expansion in MDS.

Citing Articles

Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes.

Wang M, Liao C, Wei X, Xie Y, Han P, Yu Y PLoS One. 2025; 20(3):e0315408.

PMID: 40073065 PMC: 11902259. DOI: 10.1371/journal.pone.0315408.


Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.

Zhao A, Zhao M, Qian W, Liang A, Li P, Liu H Front Immunol. 2023; 13:1063986.

PMID: 36713414 PMC: 9880439. DOI: 10.3389/fimmu.2022.1063986.


RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.

Kaisrlikova M, Vesela J, Kundrat D, Votavova H, Dostalova Merkerova M, Krejcik Z Leukemia. 2022; 36(7):1898-1906.

PMID: 35505182 PMC: 9252911. DOI: 10.1038/s41375-022-01584-3.


Upregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients with Ovarian Cancer.

Chen R, Cao J, Jiang W, Wang S, Cheng J J Oncol. 2021; 2021:7548406.

PMID: 34594380 PMC: 8478559. DOI: 10.1155/2021/7548406.


DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.

Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S Blood Adv. 2021; 5(2):438-450.

PMID: 33496740 PMC: 7839369. DOI: 10.1182/bloodadvances.2020001461.